67 results about "Disease stages" patented technology

Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.

A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays, the software including analyzing means for analyzing the arrays.

A system (100) and method is provided for performing a model-based segmentation of an anatomical structure in a medical image of a patient. The medical image (022) is accessed. Moreover, model data (162) is provided which defines a deformable model for segmenting the type of anatomical structure. The model-based segmentation of the anatomical structure is performed by adapting the deformable model to the anatomical structure in the medical image using an adaptation technique. In accordance with the present invention, performing the model based segmentation further comprises determining from patient data (042) medical information which is predictive of an appearance of the anatomical structure in the medical image, and adjusting or setting a segmentation parameter based on the medical information so as to adjust the model-based segmentation to said predicted appearance of the anatomical structure in the medical image, the segmentation parameter being a parameter of i) the deformable model or ii) the adaptation technique. Advantageously, the system and method are enabled to better cope with the inter-patient and inter-disease-stage variability in the appearance of anatomical structures.

The present invention refers to a medical diagnostic method based on proteomic and / or genomic patterns, using data obtained by mass spectrometry. The method also allows classifying the patients as to their disease stage Additionally, present invention also refers to two new biomarkers for the Hodgkin Disease medical diagnosis. Based on the SVM analysis, one localizes the windows of interest and later on uses the mass spectrum so to allow the biomarkers localization, so that the identification of said biomarkers occur by means of a 2D gel ou by mass spectrometry.

The present invention relates to a method for improving the delivery of health care for patients. A first data signal being multimedia data which is indicative of a patient condition of a selected patient is input into a local computer. Clinical data, cost data and administrative data relating to the health of the selected patient is also input into the local computer. The first data signal is combined with the clinical data, cost data and administrative data to form a first patient information signal which is transmitted to a central computer. A predetermined disease stage is then assigned to the selected patient based on the first data signal. The disease stage is combined with the first patient information signal to form a second patient information signal. Then, a first array of risk factors is computed from a database containing a plurality of previously obtained individualized patient information records. A first predictive probability is then assigned to the selected patient based on the second patient information signal and the first array of risk factors. A first patient recommendation signal indicating one of the selected patient would benefit from immediate patient care and the selected patient would not benefit from immediate patient care is generated and then transmitted to the local computer. Both the second patient information signal and the first patient recommendation signal are transmitted to a regional computer in response to the first patient recommendation signal indicating that the selected patient requires immediate patient care.

The present invention relates to methods of diagnosing melanoma in a subject, the method comprising detecting microRNA expression levels. The present invention also relates to methods of assessing thedisease stage of melanoma and / or monitoring said melanoma stage. Also, the present invention relates to selecting a treatment or modifying a treatment based on the diagnosis or stage of melanoma. Further the present invention relates to a system for detecting and diagnosing melanoma in a patient and for determining the disease stage of melanoma.

The present invention provides methods for profiling mRNA production in single cells, in particular, during disease stages. The invention also provides a method for monitoring gene expression in a single cell which has been isolated from tissue. The methods of the present invention may be used to diagnose or monitor the progression of disease.

A system (100) and method is provided for performing a model-based segmentation of an anatomical structure in a medical image of a patient. The medical image (022) is accessed. Moreover, model data (162) is provided which defines a deformable model for segmenting the type of anatomical structure. The model-based segmentation of the anatomical structure is performed by adapting the deformable model to the anatomical structure in the medical image using an adaptation technique. In accordance with the present invention, performing the model based segmentation further comprises determining from patient data (042) medical information which is predictive of an appearance of the anatomical structure in the medical image, and adjusting or setting a segmentation parameter based on the medical information so as to adjust the model-based segmentation to said predicted appearance of the anatomical structure in the medical image, the segmentation parameter being a parameter of i) the deformable model or ii) the adaptation technique. Advantageously, the system and method are enabled to better cope with the inter-patient and inter-disease-stage variability in the appearance of anatomical structures.

A system automatically, provides a clinician with cancer specific staging criteria in response to a user selected cancer diagnosis name, calculates a stage of the disease in response to selection of particular staging criteria and associates treatments and clinical documentation with the cancer diagnosis and stage. A disease management information system includes a repository of information associating a combination of multiple disease progression indicators of a particular disease with an indicator identifying a particular stage of the particular disease. A data processor uses the repository in automatically determining a stage of a disease in a particular patient in response to receiving data identifying multiple disease progression indicators of the particular patient. The data processor stores data identifying the disease stage in a record associated with the particular patient for access by multiple healthcare workers at different locations.

A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays, the software including analyzing means for analyzing the arrays.

Methods are provided for diagnosing and / or characterizing chronic immune disease activity in a subject. In the subject methods, a sample is obtained from a subject suspected of having or known to have a chronic immune disease. The sample is then assayed for the presence of low molecular actin fragments. The assay results are used to diagnose the presence of chronic immune disease activity and / or characterize chronic immune disease activity in the subject, e.g. to confirm an initial chronic immune disease diagnosis, to determine the stage of the disease, to monitor disease progression, to predict disease attacks, and the like. Also provided by the subject invention are kits for practicing the methods.

The present invention relates to an in vivo equine disease model for equine herpesvirus-1 neurological disease comprising a horse having a low pre-exposure level of herpesvirus-specific CTL precursors and / or is approximately 20 years of age or older wherein the horse is experimentally infected with a neuropathogenic strain of equine herpesvirus or a mutant thereof. The invention includes a method of preparing an in vivo equine disease model for equine herpesvirus-1 neurological disease comprising obtaining a horse that possesses low pre-infection levels of EHV-1 specific CTL precursors and / or is approximately 20 years of age or older and inoculating the horse intranasally with an effective infecting amount of a neuropathogenic strain of EHV-1. A particularly preferred method involves the advanced neurological disease stage when the experimental horse presents clinical signs of myeloencephalopathy. Additionally, the invention concerns a method of quantifying the risk factors and predicting the development of clinical neurologic signs of equine herpesvirus-1 neurological disease in a horse comprising the steps of (a) determining the pre-infection CTLp frequency to be less than approximately 40 EHV-1 specific CTLp per 106 PBMC; and (b) determining the post-infection viremic load following exposure to EHV-1 to be approximately 10-fold or more over the viremic load present in horses following exposure to a non-neuropathogenic strain of EHV-1. Also described in the invention is the determination of the risk of developing the clinical neurologic signs by use of an equation y=a+bx wherein y is the peak viremic load, a=2.97, b=−0.027 and the variable x is the pre-infection CTLp frequency. Lastly, the invention deals with a new live, attenuated vaccine formulation that is effective against neurologic disease due to equine herpesvirus-1.